drugset / Trial / NCT05700955
Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to test the safety of Pembrolizumab and Temozolomide in treating recurrent glioblastoma and to characterize the effect of this treatment on the participants tumor and immune system..
Timeline
- Start
- 2022-11-01
- Primary completion
- 2025-01
- Completion
- 2025-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Temozolomide | Small molecule | — | Oral |